Hims & Hers Health, Inc. (NYSE: HIMS ) has hit a bumpy ride over the last year, with the stock stuck in a range from $40 to $70. The online health and wellness platform has faced a lot of questions regarding compounding GLP-1s, with the latestAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in HIMS over the next 7 ...

Hims & Hers Health, Inc. (NYSE: HIMS ) has hit a bumpy ride over the last year, with the stock stuck in a range from $40 to $70. The online health and wellness platform has faced a lot of questions regarding compounding GLP-1s, with the latestAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in HIMS over the next 7 ...